США - англійська - NLM (National Library of Medicine)

a-s medication solutions - ulipristal acetate (unii: yf7v70n02b) (ulipristal - unii:6j5j15q2x8) - ella is a progesterone agonist/antagonist emergency contraceptive indicated for prevention of pregnancy following unprotected intercourse or a known or suspected contraceptive failure [see dosage and administration (2.1)] . e lla is not intended for routine use as a contraceptive. ella is contraindicated for use in the case of known or suspected pregnancy [see use in specific populations (8.1)]. risk summary ella is contraindicated for use during an existing or suspected pregnancy. no signal of concern regarding pregnancy complications was found in postmarketing studies [see data ]. isolated cases of major malformations in ella- exposed pregnancies were identified; however, the data are not sufficient to determine a risk for birth defects with inadvertent use of ella during pregnancy. miscarriage was reported in 14% of the known pregnancy outcomes; a rate that is similar to the u.s. background rate for miscarriage.  in the u.s. general population, the estimated background risk of major birth defects and

США - англійська - NLM (National Library of Medicine)

rpk pharmaceuticals, inc. - ulipristal acetate (unii: yf7v70n02b) (ulipristal - unii:6j5j15q2x8) - ella is a progesterone agonist/antagonist emergency contraceptive indicated for prevention of pregnancy following unprotected intercourse or a known or suspected contraceptive failure [see dosage and administration (2.1)] . e lla is not intended for routine use as a contraceptive. ella is contraindicated for use in the case of known or suspected pregnancy [see use in specific populations (8.1)]. risk summary ella is contraindicated for use during an existing or suspected pregnancy. no signal of concern regarding pregnancy complications was found in postmarketing studies [see data ]. isolated cases of major malformations in ella- exposed pregnancies were identified; however, the data are not sufficient to determine a risk for birth defects with inadvertent use of ella during pregnancy. miscarriage was reported in 14% of the known pregnancy outcomes; a rate that is similar to the u.s. background rate for miscarriage.  in the u.s. general population, the estimated background risk of major birth defects and

Бангладеш - англійська - DGDA (Directorate General of Drug Administration)

nuvista pharma ltd - ulipristal acetate - tablet - 30 mg

Сінгапур - англійська - HSA (Health Sciences Authority)

zuellig pharma pte. ltd. - ulipristal acetate micronized - tablet - 5.00mg - ulipristal acetate micronized 5.00mg

Велика Британія - англійська - MHRA (Medicines & Healthcare Products Regulatory Agency)

gedeon richter (uk - ulipristal acetate - tablet - 5mg

Сінгапур - англійська - HSA (Health Sciences Authority)

hyphens pharma pte. ltd. - ulipristal acetate - tablet - 30.00 mg - ulipristal acetate 30.00 mg

Європейський Союз - англійська - EMA (European Medicines Agency)

laboratoire hra pharma - ulipristal - contraception, postcoital - sex hormones and modulators of the genital system, , emergency contraceptives - emergency contraception within 120 hours (five days) of unprotected sexual intercourse or contraceptive failure.

Велика Британія - англійська - MHRA (Medicines & Healthcare Products Regulatory Agency)

hra pharma uk ltd - ulipristal acetate - tablet - 30mg

Малайзія - англійська - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

zuellig pharma sdn bhd - ulipristal acetate -

Канада - англійська - Health Canada

laboratoire hra pharma - ulipristal acetate - tablet - 30mg - ulipristal acetate 30mg - contraceptives